Innate Pharma jumps on FDA's 'breakthrough therapy' tag for skin cancer therapy

Innate Pharma SA

18/02/2025 11:59

** U.S-listed shares of drug developer Innate Pharma
 IPH.PA   IPHA.O  rise 32.8% to $2.59 premarket
    ** On Monday, the U.S. FDA granted "breakthrough therapy"
designation to co's experimental skin cancer therapy, lacutamab,
to treat patients with Sézary syndrome who didn't respond to
prior treatments or experienced a recurrence
    ** The FDA's tag is meant to speed up development and review
of drugs to treat a serious condition or unmet medical need
    ** Co said it is working with regulatory agencies to move
forward with a late-stage trial and is seeking a partner
    ** Co fell 32.3% in 2024

 (Reporting by Kamal Choudhury in Bengaluru)
 ((Kamal.Choudhury@thomsonreuters.com;))